BACKGROUND: The response rate of advanced or recurrent @entity356 to @entity11730 (TS-1) is 46.5%, which is higher than the response rate of this type of @entity5 to any other anticancer agent. However, the incidence of adverse reactions to this drug has also been reported to be as high as 83.2%. According to a postmarketing survey, adverse reactions to this drug begin to appear 2-3 weeks after the start of drug administration. With these findings in mind, we recently devised a new dosing regimen for the drug, by which the drug is administered for 2-week periods separated by 1-week drug-free intervals (the 2-week regimen). The aim of this retrospective study was to evaluate the efficacy and feasibility of the 2-week regimen in comparison with a 4-week dosing regimen with a 2-week interval between sessions (the 4-week regimen) as the historical control. METHODS: The subjects were 27 @entity1 with advanced or recurrent @entity356 who received @entity11730 therapy at our center between September 1999 and November 2001. Of these @entity1 , 14 who received the 4-week regimen before January 2001 served as historical controls, and the results in these @entity1 were compared with those of the remaining 13 @entity1 , who received the 2-week regimen after February 2001. @entity1 backgrounds, adverse reactions, compliance, and efficacy were investigated retrospectively. RESULTS: The incidence of adverse reactions tended to be lower in the 2-week-regimen group (77%) than in the 4-week-regimen group (93%). The percentage of @entity1 who received the drug for 6 months in complete compliance with the dosing schedule, as calculated by the Kaplan-Meier method, was 85% in the 2-week-regimen group and 40% in the 4-week-regimen group. The response rate to the drug was 23% in the 2-week-regimen group and 21% in the 4-week-regimen group. CONCLUSION: These results suggest that this 2-week regimen may mitigate adverse reactions and prolong the medication period.

A new regimen for XXXX therapy aiming at adverse reaction mitigation and prolonged medication by introducing a 1-week drug-free interval after each 2-week dosing session: efficacy and feasibility in clinical practice.

@entity5 :: ('MESH:D009369', 'Disease') :: ['cancer'] @entity1 :: ('9606', 'Species') :: ['patients', 'Patient'] @entity356 :: ('MESH:D013274', 'Disease') :: ['gastric cancer'] @entity11730 :: ('5707', 'Gene') :: ['S-1']
@entity11730 :: (5707,Gene) :: ['S-1']
